CIK 0001841387 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Returned to the company 10% owner returned 200,000 shares (to the company)
- 4 Returned to the company 10% owner returned 350,000 shares (to the company)
- 4 Open-market buy Director bought 1,250,000 shares at $6.00 ($7,500,000)
- SC 13G Stake Amended Statement of Ownership
- 4 Returned to the company 10% owner returned 800,000 shares (to the company)
- 8-K Event Material agreement · Other events
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- 8-K Event Regulation FD disclosure · Other events
- 4 Returned to the company 10% owner returned 60,000 shares (to the company)
- 4 Open-market sale Chief Technology Officer sold 20,392 shares at $4.56 ($92,898)
- 4 Open-market sale Chief Executive Officer sold 48,847 shares at $4.56 ($222,527)
- 4 Open-market sale Chief Medical Officer sold 13,935 shares at $4.56 ($63,482)
- 4 Open-market sale Chief Scientific Officer sold 22,081 shares at $4.56 ($100,592)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
Page 9 of 22 · 422 filings